SR-8541A + nivolumab

SR-8541A + nivolumab is a **combination therapy** consisting of SR-8541A, a potent, orally available small molecule inhibitor of the enzyme **Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)**, and **nivolumab**, a fully human **monoclonal IgG4 antibody** that acts as an **immune checkpoint inhibitor** targeting **programmed cell death protein 1 (PD-1)**. SR-8541A, developed by Stingray Therapeutics, promotes STING pathway activation, stimulates type I interferon and chemokine expression, and augments anti-tumor immunity by increasing immune cell infiltration and modulating the tumor microenvironment. Nivolumab, primarily developed by Bristol Myers Squibb, blocks PD-1 interaction with its ligands (PD-L1, PD-L2) to restore T-cell activity and enhance immune-mediated anti-tumor responses. The combination is being studied in advanced/metastatic solid tumors and is expected to synergistically enhance immune activation, particularly in tumor types where monotherapy checkpoint inhibition is ineffective or resistance has developed.

Brand names

Opdivo

Other names

ENPP1 inhibitor + nivolumabimmune checkpoint inhibitor combination therapy